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ApoE receptorVery Low Density Lipoprotein Receptor (VLDLR) is an apolipoprotein E receptor involved in synaptic plasticity,
learning, and memory. However, it is unknown how VLDLR can regulate synaptic and cognitive function. In
the present study,we found that VLDLR is present at the synapse both pre- andpost-synaptically. Overexpression
of VLDLR signiﬁcantly increases, while knockdown of VLDLR decreases, dendritic spine number in primary hip-
pocampal cultures. Additionally, knockdown of VLDLR signiﬁcantly decreases synaptophysin puncta number
while differentially regulating cell surface and total levels of glutamate receptor subunits. To identify the mech-
anism bywhich VLDLR induces these synaptic effects, we investigatedwhether VLDLR affects dendritic spine for-
mation through the Ras signaling pathway, which is involved in spinogenesis and neurodegeneration.
Interestingly, we found that VLDLR interacts with RasGRF1, a Ras effector, and knockdown of RasGRF1 blocks
the effect of VLDLR on spinogenesis. Moreover, we found that VLDLR did not rescue the deﬁcits induced by the
absence of Ras signaling proteins CaMKIIα or CaMKIIβ. Taken together, our results suggest that VLDLR requires
RasGRF1/CaMKII to alter dendritic spine formation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In addition to participating in cholesterol transport, apolipoprotein E
(ApoE) receptors have been implicated in neuronal development,
synaptic function, and Alzheimer's disease (AD). Two of these receptors
with 50%homology to one another, ApoE Receptor 2 (ApoER2) andVery
Low Density Lipoprotein Receptor (VLDLR), are important for nervous
system development [1–4]. Speciﬁcally, the double ApoER2 and VLDLR
knockout caused deﬁcits in neuronal migration in the developing
brain [5]. Polymorphisms in VLDLR have also been associated with
Alzheimer's disease risk later in life [6]. Moreover, the gene encoding
for the ligand of this receptor, APOE, is the strongest known genetic
risk factor for Alzheimer's disease [7].
In addition to their roles in neuronal development and disease, ApoE
receptors have also been implicated in synaptic function. In particular,, Department of Neuroscience,
ington, DC 20057-1464, USA.
BRI), Jungang-daero, Jung-gu,ApoER2 knockout mice demonstrate severe defects in LTP and dentate
granule cell organization while the VLDLR knockout mice have moder-
ate defects in the hippocampus [8,9]. Moreover, we have previously
shown that ApoER2 can alter dendritic spine formation with different
cytoplasmic adaptor proteins moderating this effect [10]. Blocking the
function of another ApoE receptor, low-density lipoprotein receptor-
related protein-1 (LRP1), can also induce deﬁcits in the late phase of
LTP [11] and decrease dendritic spine density [12]. Taken together,
this research suggests that ApoE receptors are important in synapse
function and dendritic spine formation, and therefore, in learning and
memory. However, it is unknown whether VLDLR alters dendritic
spines. Moreover, the molecular mechanisms by which ApoE receptors
could alter spinogenesis are still unknown.
In the present study, we are the ﬁrst to demonstrate the effect of
VLDLR on dendritic spine number and its expression at pre- and post-
synaptic densities. Additionally, we discovered that VLDLR selectively
affects the puncta number of synaptophysin as well as the expression
of glutamatergic receptors at the synapse. Moreover, we report that
the knockdown of Ras signaling proteins RasGRF1, CaMKIIα or CaMKIIβ
block the effect of VLDLR on mediating spine density. Taken together,
our results suggest that VLDLR increases dendritic spine density
through a RasGRF1/CaMKII-dependent signaling mechanism.
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2.1. Mus musculus
VLDLR knockout mice were raised from stocks originally created
through targeted gene deletion [13]. All experiments used wild-
type littermates as controls. The animals were provided a standard
rodent chow diet (Diet 7001, Harlan Teklad, Madison, WI) and
water ad libitum. All procedures were performed in accordance
with the protocols approved by the Institutional Committee for Use
and Care of Laboratory Animals of the University of South Florida
and the Animal Care and Use Committee of Georgetown University.
2.2. Cell lines and culture conditions
COS7 cells (Lombardi Co-Resources Cancer Center, Georgetown Uni-
versity, Washington DC, USA) were maintained in Opti-MEM
(Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS,
Invitrogen, Carlsbad, CA, USA.) in a 5% CO2 incubator. To examine chang-
es in cell surface levels of VLDLRbyRasGRF1, COS7 cellswere transiently
transfected with VLDLR+ Vector or VLDLR+ RasGRF1, using FuGENE 6
(Roche, Indianapolis, IN, USA) according to the manufacturer's protocol
followed by cell surface biotinylation. After 24 h, cell surface biotinyl-
ation was conducted as previously described ([10]).
2.3. Antibodies
We used the following antibodies: anti-PSD-95 (Chemicon Billerica,
MA, USA), anti-GFP (Invitrogen Carlsbad, CA, USA), β-actin (Chemicon,
Temecula, CA, USA), anti-GluA1 (Calbiochem. Darmstadt, Germany),
anti-GluA2 (Chemicon, Billerica,MA), anti-c-myc (Abcam, San Francisco,
CA, USA), anti-synaptophysin (Sigma, St. Louis, MO, USA), anti-VLDLR
(5F3, generous donation from Dr. Dudley Strickland; IIII, generated in
the laboratory of Dr. Guojun Bu; 74, generous gift from Dr. Joachim
Herz), anti-GluN1 (Neuromab, UC Davis, Davis, CA, ISA), anti-
GluN2A (Chemicon Temecula, CA, USA), anti-GluN2B (Neuromab,
UC Davis, Davis, CA, USA), anti-Ras (BD Biosciences, San Jose, Ca,
USA), anti-RasGRF1 (BD Biosciences, San Jose, CA, USA, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-CaMKIIα (Abcam, San
Francisco, CA, USA), anti-p-CaMKIIα (Abcam, San Francisco, CA,
USA), CaMKIIβ (Abcam, San Francisco, CA, USA).
2.4. Primary neuronal culture and transfection
Hippocampal neurons from embryonic day 18–19 Sprague–Dawley
rats (Rattus norvegicus) were cultured at 150 cells/mm2 as described
[14]. These cells are mixed cultures, as no glial inhibitor is added to
the media. To test the effect of VLDLR on spinogenesis, primary hippo-
campal cultures were transfected with GFP + vector, GFP + VLDLR, or
GFP + VLDLR shRNA using lipofectamine 2000 (Invitrogen). After 72 h,
dendritic spine density was measured using Scion ImageJ. To examine
which domain of VLDLR is responsible for its effect on spinogenesis, pri-
mary hippocampal neurons were transfected with GFP + vector,
GFP + VLDLR deletion #1 (without VLDLR ligand binding domain),
GFP + VLDLR deletion #2 (without VLDLR extracellular domain),
GFP + full length VLDLR for 72 h, and spine density was measured. To
measure the number of excitatory synapses, primary hippocampal neu-
ronswere transfectedwith GFP+vector, GFP+VLDLR, or GFP+VLDLR
shRNA for 72 h. After 72 h, the puncta number of synaptophysin and
PSD-95wasmeasured, aswell as spinogenesis related proteins. To exam-
ine whether VLDLR promotes spinogenesis in a RasGRF1-dependent
manner, primary hippocampal neurons were transfected with
GFP + Vector + PLL, GFP + VLDLR + Vector, GFP + RasGRF1
shRNA + Vector, GFP + RasGRF1 shRNA + VLDLR for 72 h, and spine
density was measured. To test the effect of CaMKIIα and CaMKIIβ on
VLDLR mediated spinogenesis, primary hippocampal neurons weretransfected with GFP + PLL + Vector, GFP + VLDLR+ Vector,
GFP + CaMKIIα or CaMKIIβ shRNA + Vector, or GFP + VLDLR +
CaMKIIα or CaMKIIβ shRNA for 72 h, and dendritic spine density was
measured.
2.5. Spine density analysis
For quantiﬁcation of spine number, images of the dendritic shaft
were collected at 63× magniﬁcation in the GFP channel. Groups were
coded to prevent bias, and dendritic spines were counted on 100 μm
dendritic segments (one to three dendritic shafts per neuron). The
numbers of spines were divided by the length measured to measure
the density along the dendritic shaft. The spinemeasurementswere col-
lected from at least 8 neurons per group. For each construct, individual
spine measurements were ﬁrst grouped and averaged per neuron;
means from several neurons were then averaged to obtain a population
mean (presented as mean ± SEM).
2.6. Plasmids
The VLDLR shRNA constructs were a gift from Dr. Tracy Young-
Pearse. The following was the target sequence for VLDLR shRNA #1:
5′-CCGGCCAGCAATGAACCTTGTGCTACTCGAGTAGCACAAGGTTCATTG
CTGGTTTTTG-3′, for VLDLR #3: 5′-CGGGCCGAGTCTGATCTTCACTAACT
CGAGTTAGTGAAGATCAGACTCGGCTTTTTG-3′ and the shRNAs were
expressed in a pLKO.1 plasmid vector. The CaMKIIα and β RNAi con-
structs were gifts from Dr. Dan Pak at Georgetown University.
The following sequences were targeted: for CaMKIIα; 5′-CCACTACC
TTATCTTCGAT-3′; for CaMKIIβ; 5′-GAGTATGCAGCTAAGATCA-3′ and
the RNAi were expressed in the pSuper plasmid vector. The VLDLR-
myc constructs were expressed in a pSEC, tag2 hygro plasmid under
the CMV promoter. The GFP construct was expressed in the pEGF1 N1
plasmid under the CMV promoter.
2.7. Immunocytochemistry
To test the co-localization between VLDLR and various synaptic pro-
teins related to spinogenesis for Fig. 1, primary hippocampal neurons
(DIV 21) were ﬁxed with 4% paraformaldehyde for 5 min, and with
methanol for 5 min. After ﬁxation, cells were washed with 1× PBS
three times, and then incubated with primary antibody overnight
(VLDLR (IIII) and one of the following antibodies: synaptophysin, PSD-
95). Images were taken on a single plane using a confocal microscope
(Zeiss LSM 510). To measure synaptic protein intensity, primary
hippocampal neurons were ﬁxed in either 4% paraformaldehyde at
room temperature (for morphological analysis) or in methanol at
−20 °C (for immunostaining of endogenous synaptic markers) for
10 min. After ﬁxation, cells were incubated with primary antibodies
in GDB buffer (0.1% gelatin, 0.3% Triton X-100, 16 mM sodium phos-
phate pH 7.4, 450 mM NaCl) overnight. The next day, cells were
washed with 1× PBS three times, and cells were incubated in sec-
ondary antibody with AlexaFluor 488 or AlexaFluor 555. To measure
the cell surface levels of AMPA receptor subunits, live neuronal cul-
tures were incubated with antibodies directed against extracellular
N-termini of AMPA receptor subunits (GluA1, GluA2, 10 mg/mL in
conditioned medium, non-permeabilizing conditions) for 10 min.
Then, cells were ﬁxed with 4% paraformaldehyde for 5 min and
washed with 1× PBS three times. We then incubated with Alexa
Fluor 555-linked anti-mouse secondary antibodies for 1 h. Z-
stacked images from a confocal microscope (Zeiss LSM510) were
imaged and analyzed for the number of puncta and total intensity
using Metamorph and ImageJ software. Dendrites were straight-
ened using a customized macro, and puncta number was measured
in the 0-50 μm dendritic region from the soma. Puncta density was
calculated by dividing the puncta number by the area of the dendritic
branch.
Fig. 1. VLDLR is expressed at synapses. (A) Primary hippocampal neurons (DIV 21) were co-immunostained with synaptophysin (red) and VLDLR (green, IIII antibody, upper panels) or
PSD-95 (red) andVLDLR (green, IIII antibody, lower panels). (B) Immunoblot following synaptosomal fractionation for VLDLR, CAMKIIα, CAMKIIβ, RasGRF1, synaptophysin and PSD-95 in
pre-synaptic vesicles (SV) and post-synaptic density (PSD) fractions. (C) Immunoblot comparing VLDLR levels inwild-type (WT) and VLDLR knockout (KO) tissue using VLDLR antibodies
α-IIII (left), α-5F3 (middle), α-74 (right), and β-Actin as a loading control.
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For the Reelin treatment, primary hippocampal neurons (DIV 21)
were treated with puriﬁed recombinant mouse Reelin (50ng/ml) obtain-
ed from R&D Biosystems (Minneapolis, MN, USA) or vehicle (PBS). Fol-
lowing a 1 hour treatment, we immunoprecipitated neuronal lysates
with IIII or IgG control. Otherwise, primary cortical and hippocampal ly-
sates or whole brain lysates were incubated with anti-synaptophysin,
PSD-95, GluA1, GluA2, GluN1, GluN2A, GluN2B, CamKIIα or CaMKIIβ
and protein G- or protein A-Sepharose beads overnight at 4 °C
(Amersham Biosciences, Pittsburgh, PA, USA). The next day, cell or
brain lysate was washed with IP buffer 3 times, and re-suspended in
SDS sample buffer, and Western blot was conducted.
2.9. Synaptosomal fractionation
Synaptosomal fractionation was performed as described [10].
Mouse brains were homogenized in Sucrose HEPES buffer (0.32 M su-
crose, 4 mMHEPES-NaOH, pH 7.3 with protease inhibitors), and centri-
fuged at 10,000 g for 10 min to recover the S1 supernatant and the P1
pellet. The S1 supernatant was subsequently spun at 12,0000 g for
15 min to obtain the P2 pellet (Crude synaptosome) and the superna-
tant S1. The P2 fraction was lysed via hypo-osmotic shock and centri-
fuged at 250,000 g for 20 min to generate the pellet LP1 and the
supernatant LS1. The LS1 fraction was ultracentrifuged to obtain the
synaptic vesicle fraction (LP2 or SV). The LP1 pellet was applied to a dis-
continuous sucrose gradient consisting of 1.0, 1.5, and 2.0 M sucrose
layers. After a 200,000 g ultracentrifugation for 2 h, the PSD fraction
was recovered at the 1.5/2.0 M sucrose interface and solubilized in de-
tergent (0.16 M sucrose, 5 mM Tris–HCl, pH 8.0, 0.5% Triton X-100,
0.5 mM β-ME, 1 mM EDTA, and protease inhibitors). This fraction was
ultracentrifuged to obtain the ﬁnal PSD2 fraction.
2.10. Statistical analyses
All data were analyzed using either a two-tailed T-test or ANOVA
with GraphPad Prism 4 software. Post-hoc analyses were completed
with Tukey's multiple comparison test with p b 0.05 signiﬁcance
(*p b 0.05, **p b 0.01, ***p b 0.001).
3. Results
3.1. VLDLR expression in synapses
To determinewhether VLDLR is expressed at the synapse, we immu-
nostained primary hippocampal neurons with VLDLR (green, IIII anti-
body) and synaptophysin (red, pre-synaptic marker) antibodies. We
found that VLDLR is expressed along the dendrites and spines with a
punctate staining that partially co-localizes with synaptophysin
(Fig. 1A, upper panels). We also conducted a parallel experiment by
staining primary hippocampal cultures with VLDLR (green, IIII anti-
body) and PSD-95 (red, post-synaptic marker) antibodies. VLDLR also
co-localized with PSD-95 (Fig. 1A, lower panels), suggesting that
VLDLR could be present in both pre- and post-synaptic compartments.
As an alternative approach to deﬁning VLDLR subcellular expression,
we conducted synaptosomal fractionations from wild-type mouse brain
lysate and probed for VLDLR as well as various synaptic proteins related
to spinogenesis. Consistent with our immunostainings, we found that
VLDLR was present in both the pre- and post- synaptic fractionations.
However, VLDLR was either more pre- or post-synaptic depending upon
the antibody used. Interestingly, we found that VLDLR was present in
both the pre- and post-synaptic fractionationswhenwe used an antibody
recognizing the ligand binding domain (LBD) of VLDLR (5F3,monoclonal)
(Fig. 1B, upper left panel). However, another polyclonal VLDLR antibody
raised against the LBD of VLDLR (IIII) predominantly localized to the
post-synaptic fractionation (Fig. 1B, second left panel). Another N-terminal antibody, recognizing the LBD for VLDLR (α-74, polyclon-
al), suggested that VLDLR is mostly localized to the pre-synaptic frac-
tionation (Fig. 1B, third left panel). To test for nonspeciﬁc binding of
these VLDLR antibodies, we probed the immunoblots of wild-type
and VLDLR knockout tissue with these three VLDLR antibodies. We
were unable to see any immunoreactivity in the VLDLR deﬁcient tis-
sue at 120 kDa, the molecular weight for VLDLR (Fig. 1C). These data
suggest that the antibody used for VLDLR is important to consider
when examining VLDLR expression at the synapse.
To screen for spinogenesis-related synaptic proteins, we exam-
ined the distribution of CaMKIIα, CaMKIIβ, and RasGRF1 (Fig. 1B,
right panel). Consistent with the literature, we found that CaMKIIα
is predominantly post-synaptic, but can also be at the pre-synaptic
compartment [15]. Likewise, CaMKIIβ and RasGRF1 are mostly
expressed at the post-synaptic density (Fig. 1B, right panel). To mon-
itor the purity of the synaptosomal fractionations, we probed for
synaptophysin and PSD-95 and found them only in the expected
compartments (Fig. 1B, lower right panel). Overall, these data sug-
gest that VLDLR can be present in both pre- and post-synaptic com-
partments of synaptosomal fractionations depending on which
region in the LBD of VLDLR is targeted.
3.2. VLDLR promotes dendritic spine formation in vitro
We and others have found that ApoE receptors, LRP1 and ApoER2,
can affect dendritic spine formation [10,12]. Here, we investigated
whether another ApoE receptor involved in learning and memory,
VLDLR, could also alter dendritic spine formation. To test this hypothe-
sis, primary hippocampal neurons (at DIV14, highest peak of in vitro
synaptogenesis) were transfected with GFP + vector, GFP + VLDLR,
GFP + PLL (control vector for shRNA) or GFP + VLDLR shRNA for 72 h
and dendritic spine density was measured. Overexpression of VLDLR
caused a trend toward increased spine density (Fig. 2A–B, p b 0.06),
while knockdown of VLDLR did not signiﬁcantly alter spine density
(Fig. 2C–D) compared to controls.
We then examinedwhether VLDLR regulated dendritic spine number
in mature neurons. For this experiment, primary hippocampal neurons
(DIV21) were transfected with GFP + Vector, GFP + VLDLR, GFP + PLL,
or GFP + VLDLR shRNA for 72 h and dendritic spine density was mea-
sured. Interestingly, we found that overexpression of VLDLR signiﬁcantly
increased spine density by 42% (Fig. 2E–F, *p b 0.05),while knockdownof
VLDLR signiﬁcantly decreased dendritic spine density by 33% (Fig. 2G–H,
***p b 0.001). These data suggest that VLDLRmay have differential effects
on dendritic spine density during stages of spine formation and stability.
To determine the effectiveness of VLDLR shRNA knockdown, we
transfected COS7 cells with rodent VLDLR and shRNA constructs. Two
VLDLR shRNA constructs (#1 and #3)were tested, but only #3was effec-
tive in reducing VLDLR expression by N90% (Fig. 2I). As an independent
assay, we also stained primary hippocampal cultures that had been
transfectedwith empty vector or with shVLDLR (Fig. 2J). After shRNA ex-
posure, we observed a large reduction in VLDLR staining compared to
control, validating the speciﬁc pattern of VLDLR staining (Fig. 1A) and
the efﬁcacy of VLDLR knockdown. For the experiments in Fig. 2, as well
as the rest of the experiments, we use this VLDLR shRNA #3 construct
(please see the Materials and methods section for more detail).
We then examined which domain of VLDLR was responsible for
its effect on dendritic spine formation. Primary hippocampal neu-
rons (DIV18) were transfected with GFP+ VLDLR deletion #1 (with-
out the ligand binding domain of VLDLR), GFP + VLDLR deletion #2
(without the extracellular domain of VLDLR; VLDLR c-terminal frag-
ment), or GFP+ full length VLDLR for 72 h followed by quantiﬁcation
of dendritic spine density (Fig. 2K–L). Deletion of the ligand binding
domain of VLDLR eliminated the effect of VLDLR on dendritic spine
density (Fig. 2L). These data suggest that VLDLR may play an impor-
tant role in spinogenesis, and speciﬁcally, that the extracellular do-
main of VLDLR is required for this effect.
Fig. 2. VLDLR promotes dendritic spine density in primary hippocampal neurons. (A, C) Primary hippocampal neurons were transfectedwith GFP+ Vector (n= 12), GFP+ VLDLR (n=
10), GFP+PLL (control vector for shRNA, n=5), orGFP+VLDLR shRNA (n=4), for 3 days. Cells (DIV 14)were then ﬁxed, immunostained for GFP, and dendritic spineswere counted on
primary dendrites. (B, D) Quantiﬁcation of A and C. (E, G) Hippocampal neurons (DIV18) were transfected with GFP + Vector (n = 10), GFP + VLDLR (n = 8), GFP + PLL (n = 8), or
GFP + VLDLR shRNA (n = 8) for 3 days. Cells (DIV 21) were then ﬁxed, immunostained with GFP, and dendritic spines were counted on primary dendrites. (F, H) Quantiﬁcation of E
and G (*p b 0.05, ***p b 0.001). (I) COS7 cells were co-transfected with rodent VLDLR and VLDLR shRNA #1 or VLDLR shRNA #3 or control PLL vector. VLDLR in cell lysates was measured
with antibody IIII. (J) A representative image of hippocampal neurons (DIV 21) transfected with empty vector or VLDLR shRNA(#3) immunostained for VLDLR. (K) Schematic of the dif-
ferent deletion constructs for VLDLR. (L) Primary hippocampal neurons (DIV18) were transfected with GFP + Vector (n = 8), GFP + VLDLR construct #1 (lacking the ligand binding do-
main of VLDLR, n = 8), GFP + VLDLR construct #2 (lacking the extracellular domain of VLDLR, n = 5), or GFP + VLDLR construct #3 (full length VLDLR, n = 9). Dendritic spines were
analyzed and quantiﬁed (**p b 0.01). Error bars represented as S.E.M.
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Since we observed that VLDLR can enhance dendritic spine density,
we investigatedwhether VLDLR could affect functional synapses. To ini-
tially test this hypothesis, we examinedwhether the VLDLR IIII antibodywould be effective in co-immunoprecipitation assays. Therefore, wild-
type and VLDLR KO brain lysates were homogenized in immunoprecip-
itation (IP) buffer, immunoprecipitated with α-IIII (for VLDLR) or IgG
(negative control), and immunoblotted for α-5F3 (another VLDLR anti-
body) or α-APP (an interacting protein) as a positive control (Fig. S1A).
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immunoprecipitating VLDLR and detecting its interaction partners, we
conducted a parallel experiment to test whether VLDLR could interact
with synaptophysin or PDS-95 (Fig. 3A–B). We found that VLDLR did
not co-precipitate with either of these synaptic proteins. Although
these proteins do not interact with VLDLR, we next investigated wheth-
er VLDLR expression levels could alter the puncta number ofFig. 3. Knockdown of VLDLR signiﬁcantly decreases synaptophysin puncta number. (A–B) Mou
noblot with synaptophysin (A) and PSD-95 (B). (C) Primary hippocampal neurons (DIV12) wer
immunostained with synaptophysin (left) or PSD-95 (right). (D) Quantiﬁcation of synaptoph
(E) Quantiﬁcation of PSD-95 puncta number in C (PLL n = 6 neurons, VLDLR shRNA n = 8 n
GFP + VLDLR shRNA for 3 days. Cells were then ﬁxed and immunostained with synaptophys
n = 5 neurons, VLDLR shRNA n = 7 neurons, *p b 0.05). (H) Quantiﬁcation of PSD-95 punctasynaptophysin and PSD-95. To test this hypothesis, we transfected pri-
mary hippocampal neurons at DIV14 or DIV21 with GFP + PLL or
GFP + VLDLR shRNA for 72 h and immunostained with synaptophysin
or PSD-95 antibodies (Fig. 3C, F). Interestingly, knockdown of VLDLR
signiﬁcantly decreased synaptophysin puncta number at DIV14 and
DIV21 by approximately 30% (Fig. 3D, G, *p b 0.05). However, knock-
down of VLDLR did not alter PSD-95 puncta number at DIV14 andse brain lysates were immunoprecipitated with IgG or VLDLR (IIII) followed by an immu-
e transfectedwith GFP+ PLL or GFP+ VLDLR shRNA for 3 days. Cells were then ﬁxed and
ysin puncta number in C (PLL n = 6 neurons, VLDLR shRNA n = 7 neurons, *p b 0.05).
eurons) (F) Primary hippocampal neurons (DIV18) were transfected with GFP + PLL or
in (left) or PSD-95 (right). (G) Quantiﬁcation of synaptophysin puncta number in F (PLL
number in F (PLL n = 8 neurons, VLDLR shRNA n = 8 neurons).
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composition prior to postsynaptic alterations such as dendritic spine
formation.
3.4. VLDLR alters levels of NMDA receptor subunit GluN1
We then investigated whether VLDLR could alter other postsynaptic
markers beyond PSD-95 at the synapse. Speciﬁcally, we examined
whether VLDLR can interact with NMDA receptor subunits, which areFig. 4. Knockdown of VLDLR decreases GluN1 levels. (A-C) Mouse brain lysates were immunop
and GluN2B (C). Arrows indicate speciﬁc bands at the expected molecular weight. (D) Hip
GFP + VLDLR (n = 11 neurons) for 3 days. Cells were then ﬁxed and immunostained for GluN
grated intensity in D. (F) Hippocampal neurons (DIV18) were transfected with GFP + PLL (n
and immunostained for GluN1. Representative images for each condition are shown. (G) Qu
(DIV18)were transfectedwith GFP+ PLL or GFP+VLDLR shRNA for 3 days. Cells were ﬁxed an
in H (n = 7–16 neurons/group). (K) Quantiﬁcation of GluN2B integrated intensity in J (n = 8–involved in spinogenesis and synaptic plasticity (for review, see [16,
17]). For this experiment, wild-type brain lysates were homogenized
in IP buffer, immunoprecipitated with α-IIII (for VLDLR) or IgG (nega-
tive control), and immunoblotted with α-GluN1, α-GluN2A, or α-
GluN2B. We found that VLDLR did not co-precipitate with these
NMDA receptor subunits (Fig. 4A–C). Next, we tested whether VLDLR
altered NMDA receptor subunit levels. Primary hippocampal neurons
(DIV18) were transfected with GFP + Vector, GFP + VLDLR,
GFP + PLL, or GFP + VLDLR shRNA for 72 h and immunostained withrecipitated with IgG or VLDLR (IIII) followed by immunoblot with GluN1 (A), GluN2A (B),
pocampal neurons (DIV18) were transfected with GFP + Vector (n = 11 neurons) or
1. Representative images for each condition are shown. (E) Quantiﬁcation of GluN1 inte-
= 7 neurons) or GFP + VLDLR shRNA (n = 8 neurons) for 3 days. Cells were then ﬁxed
antiﬁcation of GluN1 integrated intensity in F (**p b 0.01). (H–K) Hippocampal neurons
d immunostained for GluN2A or GluN2B. (I) Quantiﬁcation of GluN2A integrated intensity
18 neurons/group).
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However, knockdown of VLDLR signiﬁcantly decreased GluN1 levels
by approximately 33% (Fig. 4D–G, **p b 0.01).We also conducted a par-
allel experiment with GluN2A and GluN2B, and found that knockdown
of VLDLR trended toward decreasing GluN2A levels (Fig. 4H–I, p b 0.07),
but did not alter GluN2B levels (Fig. 4J–K).
3.5. VLDLR affects cell surface levels of AMPA receptor subunit GluA1
Since we observed that VLDLR knockdown decreases the levels of
the GluN1 NMDA receptor subunit, we next investigated whether
VLDLR could alter the levels of AMPA receptor subunits. Speciﬁcally,
we examined whether VLDLR interacted with AMPA receptor subunits
GluA1 or GluA2. For this experiment, we immunoprecipitated wild-
type mouse brain lysates with anti-VLDLR (IIII) or IgG, and probed for
anti-GluA1 or GluA2. We found that VLDLR co-immunoprecipitated
with GluA1, suggesting that VLDLR may directly or indirectly interact
with GluA1 (Fig. 5A, S1B). However, VLDLR did not co-precipitate
GluA2 (Fig. 5B). We then conducted double immunostainings in prima-
ry hippocampal cultures for VLDLR and GluA1, or VLDLR and GluA2, and
found that VLDLR partially co-localizedwith GluA1 and GluA2 in puncta
along neuronal processes (data not shown).
To examine the effect of VLDLR on AMPA receptor subunit traf-
ﬁcking, we transfected primary hippocampal neurons with
GFP + PLL or GFP + VLDLR shRNA for 72 h and conducted live cell
surface staining (non-permeabilizing conditions) or total immuno-
staining (permeabilizing conditions) with an N-terminal recognizing
GluA1 or GluA2 antibody.We found that knockdown of VLDLR signif-
icantly decreased the cell surface levels of GluA1 by 19%, without
changing total levels, compared to control vector (Fig. 5C–F,
*p b 0.05). Interestingly, knockdown of VLDLR did not signiﬁcantly
alter cell surface or total levels of GluA2 (Fig. 5G–J). These data sug-
gest that VLDLR differentially interacts with glutamate receptor sub-
units in addition to altering glutamate receptor subunit trafﬁcking.
3.6. VLDLR requires Ras activation for altering dendritic spine density
Ras signaling is implicated in dendritic spine formation as well as
neurodegeneration such as Alzheimer's disease (AD). Speciﬁcally,
protein-speciﬁc guanine nucleotide releasing factor 1, RasGRF1, has
been linked to Ras activation, synaptic delivery of AMPA receptors,
and dendritic spine formation [18]. In a recent study, we found that
APP promotes dendritic spine formation in a Ras-dependent manner
[19], APP interacts with VLDLR, and APP affects the trafﬁcking of
VLDLR [20]. Based on the literature and our ﬁndings, we hypothesized
that VLDLR may affect dendritic spine density by regulating the levels
or activity of Ras signaling proteins.
To test this hypothesis, we ﬁrst examinedwhether VLDLR physically
associated with RasGRF1 in vivo. Wild-type brain lysates were
immunoprecipitated with IIII (for VLDLR) or IgG, and immunoblotted
for RasGRF1. We found that VLDLR co-immunoprecipitated with
RasGRF1 (Fig. 6A, S1B). We then examined whether RasGRF1 altered
the cell surface levels of VLDLR. COS7 cells were transfected with
VLDLR+ Vector or VLDLR+ RasGRF1 for 24 h and cell surface biotinyl-
ation was conducted. Overexpression with RasGRF1 did not alter cell
surface or total levels of VLDLR (Fig. 6B).
We then examinedwhether VLDLR could alter the levels of RasGRF1.
To test this hypothesis, we transfected primary hippocampal neurons
with GFP + Vector, GFP + VLDLR, GFP + PLL, or GFP + VLDLR shRNA
for 72 h. We then immunostained with RasGRF1 and found that altering
VLDLR levels did not signiﬁcantly change the levels of RasGRF1 (Fig. 6C–
F). Next, we investigated whether VLDLR required RasGRF1 to alter den-
dritic spine number. Primary hippocampal neurons were transfected
with GFP + PLL + Vector, GFP + VLDLR + Vector, GFP + RasGRF1
shRNA + Vector, or GFP + RasGRF1 shRNA + VLDLR for 72 h followed
by quantiﬁcation of spine density. Consistent with our previous ﬁndings,overexpression of VLDLR signiﬁcantly increased dendritic spine density
by 40% (Figs. 2, 6G–H, *p b 0.05). Interestingly, knockdown of RasGRF1
prevented the effect of VLDLR on spinogenesis, suggesting that VLDLR-
mediated spinogenesis requires RasGRF1 (Fig. 6G–H).
To examine whether VLDLR alters Ras activity, we conducted a
GST-pull down assay from wild-type and VLDLR knockout brain ly-
sate by incubating it with GST-Raf-RBD puriﬁed protein (the active
form of Ras) and immunoblotted for anti-Ras. We found that VLDLR
knockout brain lysates had decreased levels of the active form of
Ras compared to wild-type brain lysates (Fig. 6I). These data suggest
that the expression levels of VLDLR can affect Ras activity.
3.7. Interaction between VLDLR and CaMKIIα alters dendritic spine
formation
Ras signaling is downstream of CaMKII [20]. CaMKII induces Ras sig-
naling, which promotes dendritic spine growth and LTP [20]. Thus, we
examined whether VLDLR can interact with CaMKIIα using co-
immunoprecipitation from primary cortical neurons and wild-type
mouse brain lysate. We found that VLDLR interacted with CaMKIIα as
well as with the p-CaMKIIα (active form) in primary cortical neurons
and brain lysates (Fig. 7A (left panel), Fig. S1B). We then examined
whether VLDLR can interact with another CaMKII isoform, CaMKIIβ,
and found that VLDLR did not immunoprecipitate with CaMKIIβ
(Fig. 7A, right panel).
We examined whether CaMKIIα affected cell surface levels of
VLDLR. For this experiment, COS7 cells were transfected with
VLDLR + Vector, VLDLR + CaMKIIα WT, VLDLR + CaMKIIα T286D
(non-autophosphorylatable form) or VLDLR + CaMKIIα K42R (ki-
nase dead form) for 24 h and cell surface biotinylation was conduct-
ed. Overexpression of CaMKIIα WT increased cell surface and total
levels of VLDLR, but not CaMKIIα T286D or K42R, suggesting that
both kinase activity and phosphorylation of CaMKIIα are required
for this effect (Fig. 7B).
Next, we examinedwhether the expression levels of VLDLR can alter
the levels of CaMKIIα. To test this, we transfected primary hippocampal
neurons with GFP + Vector, GFP + VLDLR, GFP+ PLL, or GFP+ VLDLR
shRNA for 72 h and immunostained with CaMKIIα. Knockdown of
VLDLR signiﬁcantly decreased the levels of CaMKIIα by about 40%
(Fig. 7E–F, *pb 0.05),while overexpression of VLDLR trended toward in-
creasing CaMKIIα (Fig. 7C–D, p b 0.06). Based on theseﬁndings,we then
examined whether VLDLR mediated dendritic spine density through
CaMKIIα. Primary hippocampal neurons were transfected with
GFP + Vector + PLL, GFP + VLDLR + Vector, GFP + CaMKIIα
shRNA+Vector, or GFP+ VLDLR+ CaMKIIα shRNA for 72 h, and den-
dritic spine density wasmeasured. Again, we found that overexpression
of VLDLR increased dendritic spine density (Fig. 7G–H, *p b 0.05). Inter-
estingly, knockdown of CaMKIIα prevented the effect of VLDLR on
spinogenesis, suggesting that VLDLR-mediated spinogenesis is depen-
dent on CaMKIIα (Fig. 7G–H).
To testwhether VLDLR altered levels of CaMKIIβ, we transfected pri-
mary hippocampal neurons with GFP + PLL or GFP+ VLDLR shRNA for
72 h and immunostained with CaMKIIβ. Knockdown of VLDLR signiﬁ-
cantly decreased the levels of CaMKIIβ by around 25% in primary hippo-
campal neurons (Fig. 7I, *p b 0.05). We next investigated whether
CaMKIIβ could affect VLDLR enhancement of dendritic spine density.
Surprisingly, depletion of CaMKIIβ also inhibited the VLDLR-mediated
effect on dendritic spine density (Fig. 7J). Taken together, these data in-
dicate that VLDLR requires CaMKIIα and CaMKIIβ to exert its effects on
dendritic spine formation.
Reelin, an extracellular ligand of VLDLR, can also impact dendritic
spine formation, and requires either VLDLR or ApoER2 for this effect
[21,22]. Therefore, we asked whether Reelin could modulate the inter-
action of VLDLR with GluA1, RasGRF1, and/or CamKIIα. To test this,
we treated primary hippocampal neurons (DIV 21) with 50 ng/ml of
Reelin or vehicle. Following a 1 hour treatment,we immunoprecipitated
Fig. 5.Knockdown of VLDLR decreases cell surface GluA1 levels. (A, B)Mouse brain lysateswere immunoprecipitatedwith IgG or VLDLR (IIII) followed by immunoblot with GluA1 (A) and
GluA2 (B). Arrows indicate speciﬁc bands at the expected molecular weight. (C–F) Primary hippocampal neurons (DIV18) were transfected with GFP + PLL or GFP + VLDLR shRNA for
3 days. Cells were thenﬁxed in a non-permeabilizing and permeabilizing condition to detect for cell surface (C–D, PLL n=10 neurons, VLDLR shRNAn=8 neurons) and total levels (E–F,
PLL n= 9 neurons, VLDLR shRNA n= 9 neurons) of GluA1. (*p b 0.05) (G–J) Primary hippocampal neurons (DIV18) were transfectedwith GFP+ PLL or GFP+ VLDLR shRNA for 3 days.
Cells were then ﬁxed in a non-permeabilizing and permeabilizing condition to detect for cell surface levels of GluA2 (G–H, PLL n= 10 neurons, VLDLR shRNA n= 12 neurons) and total
levels of GluA2 (I–J, PLL n = 9 neurons, VLDLR shRNA n = 9 neurons).
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interacting partners (Fig. 8A). We observed that Reelin treatment de-
creased the immunoprecipitation of VLDLR with each of the binding
partners identiﬁedhere: GluA1, RasGRF1, and CamKIIα. These data indi-
cate that extracellular ligands, such as Reelin, impact the intracellular
interactions of VLDLR to the RasGRF1 signaling cascade.4. Discussion
In the present study, we identify a novel role for VLDLR on dendritic
spine formation and its mechanism of action. We found that VLDLR is
expressed at synapses both pre- and post-synaptically (Fig. 1) and
that VLDLR overexpression promotes, while VLDLR knockdown
Fig. 6. VLDLR requires RasGRF1 to mediate dendritic spine density (A) Mouse brain lysates were immunoprecipitated with IgG or VLDLR (IIII) followed by immunoblot with RasGRF1.
Arrow indicates speciﬁc band at the expectedmolecular weight. (B) COS7 cells were transfectedwith VLDLR+ Vector or VLDLR+RasGRF1, and cell surface biotinylation was performed
tomeasure cell surface levels of VLDLR (n=3/group). (C) Primary hippocampal neurons (DIV18)were transfectedwith GFP+Vector or GFP+VLDLR for 72 h. Cells were then ﬁxed and
immunostained for RasGRF1. Representative images from each condition are shown. (D) Quantiﬁcation of RasGRF1 integrated intensity from C (n = 7–10 neurons/group). (E) Primary
hippocampal neurons (DIV18)were transfectedwith GFP+PLL or GFP+VLDLR shRNA for 72 h and cells were then ﬁxed and immunostained for RasGRF1. (F) Quantiﬁcation of RasGRF1
integrated intensity from E (n = 5–11 neurons/group). (G) Primary hippocampal neurons (DIV18) were transfected with GFP + PLL + empty vector (n = 9 neurons),
GFP + VLDLR + vector (n = 10 neurons), GFP + RasGRF1 shRNA + vector (n = 11 neurons), or GFP + RasGRF1 shRNA + VLDLR (n = 10 neurons) for 72 h. After 72 h, cells were
ﬁxed and immunostained for GFP and dendritic spine density was measured. (H) Dendritic spines visualized by GFP immunostaining under the conditions in G were quantiﬁed
(*p b 0.05). (I) A GST-pulldown assay was conducted to measure the levels of active Ras from wild-type and VLDLR knockout brains (n = 3/group).
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(Fig. 2). Interestingly, we observed that VLDLR alters presynaptic puncta
number without affecting the postsynaptic puncta number (Fig. 3). Ad-
ditionally, we found that VLDLR expression selectively affects NMDA/
AMPA receptor subunit expression (Figs. 4 and 5). Moreover, VLDLR
regulates spine density, potentially by regulating Ras signaling mole-
cules, including RasGRF1 and CaMKIIα/CaMKIIβ (Figs. 6 and 7). Taken
together, our results strongly suggest that VLDLR regulates dendritic
spinogenesis in a RasGRF1/CaMKII dependent manner.
We and others have previously reported that ApoE receptors, LRP1
and ApoER2, are expressed at the synapse and regulate spinogenesis[1,10–12,22–24]. ApoER2 and VLDLR are 50% homologous, and both re-
ceptors are involved in the neural development of the neocortex
through Reelin signaling [25]. These two receptors are the exclusive
Reelin signaling receptors, and bind to Reelin with similar afﬁnities
[26]. Interactionwith Reelin induces both receptors to bind to the adap-
tor protein Dab1, which subsequently leads to the activation of Src fam-
ily tyrosine kinases [27]. Although ApoER2 and VLDLR share many
similarities, they can also interact with different ligands suggesting
that they may also have non-overlapping functions. For example,
VLDLR interacts with the Pafah1b complex, which is involved in neuro-
nal migration, while ApoER2 does not. Moreover, ApoER2 has a PDZ
Fig. 7. VLDLR interacts with CaMKIIα and requires both CaMKIIα and CaMKIIβ to alter dendritic spine formation. (A) Primary cortical neurons and mouse brain lysates were
immunoprecipitated with IgG or VLDLR (IIII) followed by immunoblot with CaMKIIα, p-CaMKIIα, or CaMKIIβ. Arrows indicate speciﬁc bands at the expected molecular weights.
(B) COS7 cells were transfected with VLDLR + Vector, VLDLR + CaMKIIαWT, VLDLR + CaMKIIα T286D (non-autophosphorylatable form), or VLDLR + CaMKIIα K42R (kinase dead
form), and cell surface biotinylation was performed to measure surface levels of VLDLR (n = 2/group). (C) Primary hippocampal neurons (DIV18) were transfected with GFP + Vector
or GFP + VLDLR for 72 h. Cells were then immunostained for CaMKIIα. (D) Quantiﬁcation of CaMKIIα levels in C (n = 7–13 neurons/group). (E) Primary hippocampal neurons
(DIV18) were transfected with GFP + PLL or GFP + VLDLR shRNA for 72 h. Cells were then immunostained for CaMKIIα. (F) Quantiﬁcation of CaMKIIα levels in E (n = 7 neurons/
group, *p b 0.05). (G) Primary hippocampal neurons (DIV18) were transfected with GFP + Vector + PLL (n = 12 neurons), GFP + VLDLR + Vector (n = 11 neurons),
GFP + CaMKIIα shRNA+ Vector (n = 7 neurons), or GFP + VLDLR + CaMKIIα shRNA (n = 11 neurons) for 72 h. Cells were then immunostained for GFP to visualize dendritic spines.
Representative images are shown. (H) Quantiﬁcation of dendritic spine density under the conditions in G (*p b 0.05). (I) Primary hippocampal neurons (DIV18) were transfected with
GFP+PLL or GFP+VLDLR shRNA for 72 h. Cells were then immunostained for CaMKIIβ. Quantiﬁcation of CaMKIIβ levels (n= 12–17 neurons/group, *p b 0.05). (J) Primary hippocampal
neurons (DIV18) were transfected with GFP + Vector + PLL (n = 12 neurons), GFP + VLDLR + Vector (n = 11 neurons), GFP + CaMKIIβ shRNA + Vector (n = 10 neurons), or
GFP + VLDLR + CaMKIIβ shRNA (n= 10 neurons) for 72 h. Cells were then immunostained for GFP to visualize dendritic spines and quantiﬁcation of dendritic spine density (*p b 0.05).
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Fig. 8. Reelin alters the interaction between VLDLR and its new interaction partners. (A) Primary hippocampal neurons (DIV21) were treatedwith control or Reelin (50 ng/ml). Following
1 hour treatment, cell lysates were immunoprecipitated with IIII or IgG and probed for GluA1 (upper panel), RasGRF1 (middle panel), CamKIIα (lower panel). As an additional negative
control, brain lysate from VLDLR knock out (−/−) were also immunoprecipitated with IIII, and loaded in the ﬁrst lane of the western blot. (B–C) A working model for how VLDLR can
promote dendritic spine formation. VLDLR (light gray rectangle) can be expressed pre- or post-synaptically. The ligand binding domain of VLDLR is necessary for the VLDLR-mediated in-
crease in dendritic spines. A recent study demonstrated that the ligands for VLDLR can promote homo- and hetero-clustering with itself or another receptor, respectively. Therefore, it is
possible that these ligands can help promote the (B) homo- or (C) hetero-clustering of VLDLR cis- or trans-synaptically. This clustering would serve as an ampliﬁcation of receptor signal-
ing, which downstream impacts the interaction of CaMKII and RasGRF1 to VLDLR, which subsequently leads to the increase in dendritic spine number.
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teract with Jip1 and PSD95. Further, the cellular distribution in mem-
brane compartments seems to be different between the two receptors,
with ApoER2 found in lipid rafts while VLDLR is usually not [28]. For a
more extensive review about the similarities and differences of these
two receptors, please see [29]. Here, we asked whether VLDLR, like
ApoER2, would also be involved in synaptic plasticity.
We are the ﬁrst to identify that VLDLR, similar to ApoER2, is
expressed at synapses and regulates dendritic spine formation
in vitro. Interestingly, we found that VLDLR more effectively alters
spinogenesis at DIV21 compared to DIV14, suggesting that VLDLR
may have amore profound impact on the later stages of spine forma-
tion or stability. We also examined whether reducing VLDLR protein
levels affects functional synapses in particular by immunostaining
with synaptophysin and PSD-95. Surprisingly, we found that VLDLR
affects synaptophysin puncta number without altering PSD-95
puncta number. Because VLDLR induces a pre-synaptic effect prior
to post-synaptic alterations (synaptophysin, DIV14; dendritic spine
density, DIV21), it is possible that the VLDLR-mediated impact on
post-synaptic spine density is an indirect effect of VLDLR inﬂuence
on pre-synaptic sites. Another possibility is that other ApoE recep-
tors known to be expressed post-synaptically (such as ApoER2)
may be altered as a compensatory mechanism when VLDLR expres-
sion is reduced. We had also conducted a parallel experiment to
test whether overexpression of VLDLR could enhance synaptic pro-
tein expression. Interestingly, we did not observe any changes in
these synaptic markers following overexpression (data not shown).
These data suggest that perhaps the overexpression of VLDLR en-
hances actin motility to increase dendritic spine number, but that
these dendritic spines may be silent and non-functional. This idea
will be further explored with functional assays such as electrophys-
iology in future experiments.
Unlike other ApoE receptors known to impact dendritic spine densi-
ty, we also observed VLDLR in the pre-synaptic compartment (Fig. 1A,
B). Moreover, depending on the antibody used, VLDLR was observed
more in the pre- or post-synaptic compartment. We tested whetherthere was differential VLDLR antibody detection for various splice vari-
ants of VLDLR (such as full length VLDLR compared to VLDLR lacking
exon 16 (the O-linked sugar domain)) (data not shown). We have not
observed that any of these antibodies differentially recognize VLDLR
splice variants. This observation does not exclude the possibility that
other splice variants or dimerization of the receptor could be themech-
anistic explanation for the variation in pre-synaptic and post-synaptic
VLDLR identiﬁcation by different antibodies. Because we observed that
2 out of 3 different N-terminal antibodies for VLDLR detected VLDLR
predominantly in the pre-synaptic compartment and it is known that
VLDLR can be cleaved by γ-secretases, it would be interesting to inves-
tigate whether this cleavage results in enhanced pre-synaptic signaling.
Future studies will elucidate these ﬁndings by measuring whether
secretase activity can alter VLDLR localization at the synapse, subse-
quently altering synapse formation in vitro and in vivo.
Much of the research regarding APOE receptor ligands (i.e., ApoE,
F-spondin, Reelin) at the synapse has focused on modulations of
post-synaptic signaling, highlighting that post-synaptic alterations can
indirectly impact pre-synaptic ones (and vice versa). Pre-synaptic
localization of VLDLR may hint at a new role for APOE receptors.
Synaptophysin levels are affected byAPOEgenotype following lipopoly-
saccharide injection [30], increased by F-spondin overexpression in an
AD model [31], and decreased with Reelin inhibition [32]. VLDLR may
be involved in the mechanism for these observations.
To further investigate the effect of VLDLR at the synapse, we also ex-
amined the effects of VLDLR on NMDA and AMPA receptor levels. Our
results demonstrate that VLDLR knockdown decreased the total levels
of GluN1 and the surface levels of GluA1 in primary hippocampal neu-
rons. These results suggest that although PSD-95 is unaffected, VLDLR
can still impact the composition of postsynaptic densities. To support
ourﬁndings, VLDLR knockoutmicewere observed to havemoderate de-
creases in synaptic potentiation [8]. It is possible that the shift of AMPA
and NMDA receptor subunit composition contributes to this effect. In-
deed, it is well known that GluA1/A2 heteromers comprise the predom-
inant AMPA receptor population in the hippocampus [33,34]. The
decrease in surface expression of the GluA1 subunit may reﬂect a shift
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of the AMPA receptors. Moreover, studies have shown that minor alter-
ations in GluN1 levels can cause changes in synaptic signaling such as
LTP [35,36].
Intriguingly, we also observed that VLDLR co-precipitated with
the GluA1 receptor subunit, but not with GluA2 or the NMDA recep-
tor subunits (Figs. 4, 5). This suggests that VLDLR may directly or in-
directly complex with GluA1 to alter both its trafﬁcking to the cell
surface and its signaling. Reelin, a ligand for VLDLR, is known to
enhance GluA1 composition through VLDLR and ApoER2 receptor
signaling [37]. However, how Reelin enhances surface GluA1 expres-
sion is unknown. These new ﬁndings shed light onto a potential
mechanism for this effect.
To elucidate the molecular mechanism by which VLDLR could pro-
mote synapse formation, we examined Ras signaling as a potential
downstream target. The Ras family of signaling molecules is important
for spine dynamics and synaptic plasticity, with Ras promoting surface
delivery of AMPA receptors and stimulating dendritic spine formation
[18,38,39]. Our grouphas recently shown that APP, a receptor that inter-
acts with VLDLR [40], co-precipitates with RasGRF1, a downstream gua-
nine exchange factor, which activates Ras signaling [19]. Moreover,
RasGRF1 is required for APP to modulate dendritic spine formation
[19]. In the present study, we found that VLDLR can also co-precipitate
with RasGRF1 (Fig. 6A), and that RasGRF1 is required for the effects of
VLDLRon dendritic spine formation. These results indicate that RasGRF1
is a potential downstream signaling molecule of VLDLR. Furthermore,
we also observed that VLDLR knockout animals have signiﬁcantly re-
duced levels of the activated form of Ras, although total Ras levels are
unchanged (Fig. 6I). These ﬁndings further contribute to the idea that
Ras activity is downstream of VLDLR signaling.
CaMKII is another molecule implicated in synaptic efﬁcacy andmor-
phogenesis [41–45]. The CaMKIIα isoform is usually associated with
synaptic efﬁciency and the CaMKIIα and β isoforms are associated
with dendritic spine morphogenesis [41–43,46]. Interestingly, overex-
pressing CaMKII also caused an increase in VLDLR expression levels;
however, it is not clear whether this is a direct or indirect effect. For ex-
ample, it is known that CAMKIIα overexpression can cause increases in
synaptic strength and size [47]. Therefore, it is possible that the increase
in spine size can in turn lead to an additional increase in VLDLR. We re-
port here that CaMKIIα, but not CaMKIIβ, interacts with VLDLR in brain
lysates. However, both CaMKII isoforms are required for the VLDLR-
mediated increase in dendritic spine density in vitro (Fig. 7). Because
VLDLR and APP can form a complex, our future studies will investigate
whether VLDLR and APP cooperate or compete to alter spinogenesis
through these signaling pathways.
A recent study showed that ligands to ApoE such as F-spondin or
Reelin could cause ApoER2 to homo-cluster with itself or hetero-
cluster with VLDLR [48]. Therefore, it is possible that the ligand-
binding domain that is required to observe the VLDLR-mediated effect
on dendritic spines (Fig. 2) could be through this same mechanism. In
our working model (Fig. 8 B,C), VLDLR may be clustering trans- or cis-
synaptically through the ligand binding domain, providing structural
support for dendritic spine growth. Moreover, this interaction of
VLDLRwith another VLDLR receptor, or with known interaction binding
partners (such as APP or ApoER2), has already been implicated in syn-
aptic development. Transient extracellular ligand treatment also altered
intracellular signaling cascades by decreasing the interaction of VLDLR
with RasGRF1 signaling proteins in addition to altering dendritic spine
formation.
What is the biological signiﬁcance of our ﬁndings? VLDLR has
been identiﬁed as an AD risk gene in Japanese cohorts [6,49], and
European Caucasian cohorts [50–52]. Moreover, VLDLR deletions
have been associated with a non-progressive cerebellar ataxia with
intellectual disability in the human population [53]. There has been
no thorough investigation of the impact of this VLDLR homozygous
deletion on dendritic spines in the hippocampal regions. Therefore,it is possible that the signaling pathways identiﬁed here may con-
tribute to both of these diseases. Moreover, these studies begin to
clarify the molecular mechanism by which the ApoE receptor family
may participate in the development and functional maintenance of
the nervous system. In particular, these studies highlight a novel
role for VLDLR at the synapse and its mechanism of action.
5. Conclusions
In summary, our results demonstrate that VLDLR alters dendritic
spine formation through a RasGRF1/CaMKII dependent mechanism.
This discovery and characterization of a novel role for VLDLR at the syn-
apse is critical to furthering our understanding of central nervous sys-
tem development and functional maintenance.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.01.015.
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